Any heart condition that leads to a sudden slowing or blockage of blood supply to the heart is referred to as an acute coronary syndrome (ACS). If you have chest pain (angina), or pressure in your chest typical of a heart attack, then you are considered as having ACS until proven otherwise. ACS is a...
Search
Displaying 121 - 140 of 1577
Family medicine is an important setting for managing cardiovascular risk factors and preventing the onset of heart disease, as well as managing risk factors following a cardiac event. If a patient is a smoker, explained Dr. Andrew Pipe, Chief of Prevention and Rehabilitation at the University of...
David Adderley is an Elected Director of the University of Ottawa Heart Institute Board.
George Addy is an Elected Director of the Board of Directors at the University of Ottawa Heart Institute.
You will ensure efficient administrative operations within our service, allowing our specialists to focus on patient care, research, and education.
With approachable and accessible program directors and excellent support from faculty and current fellows, the University of Ottawa Heart Institute's Adult Cardiology Postgraduate Training Programs provide an effective and receptive fellowship environment.
A congenital heart defect is a malformation of the heart that is present at birth. Some congenital heart defects are very minor and will never cause health problems. Others are very serious and complicated. These defects are usually discovered in infancy or early childhood due to symptoms and may be...
The Adult Congenital Heart Disease (ACHD) Clinic at the University of Ottawa Heart Institute (UOHI) specializes in the ongoing care and treatment of adult patients with congenital heart disease. Congenital heart disease (CHD) affects nearly one in 100 babies. There are many types of CHD. Whether a...
Research is focused on: a) accuracy, b) patient outcomes, 3) cost and cost-effectiveness and d) safety.
The Aerospace and Dive Cardiology Clinic at the University of Ottawa Heart Institute (UOHI) is a specialized outpatient clinic for the cardiac care of individuals who participate in activities or work in environments that place unique stresses on their cardiovascular system.
Following Burgon’s talk at the International Forum, Philip Devereaux of McMaster University spoke about Canada’s unique place in the world of cardiovascular medicine. Not only is cardiovascular disease (CVD) the leading cause of death globally but by 2020, the incidence in developing countries is...
The CARDIoGRAM consortium, of which the Heart Institute is a founding member, reported finding 13 new genetic regions associated with increased risk for coronary artery disease and heart attack. CARDIoGRAM brings together research teams from around the world to pool data sets and increase their...
Dr. Ruth McPherson, an active CARDIoGRAM participant and a co-author on the interferon biomarker study, was honoured by the AHA Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) with its Special Recognition Award. Dr. McPherson, a tireless clinician and scientist, directs the...
Mutations in the gene are associated with striated muscle diseases such as cardiomyopathy and muscular dystrophy. Filling in the unknowns about a previously unexplored gene is a good way to get the attention of your peers. Heart Institute scientist Patrick Burgon is doing just that with a gene he...
The State of the Science Lecture on Women and Heart Disease by Anne Rosenfeld of the Oregon Health Sciences University made it clear that there is much to learn about the ways the disease is unique to women. What we do know indicates that risk, symptoms, progression and treatment of CVD are all...
Successfully managing heart failure is one the looming issues for cardiovascular medicine, with prevalence expected to grow significantly over the coming decades. The plenary session “Engineering Success in Heart Failure” looked at where things are headed, from therapy to devices to delivery of care...
Once again, the University of Ottawa Heart Institute had more than 40 clinical and research presentations on the program at the annual American Heart Association Scientific Sessions. These, along with other major developments in the world of cardiovascular medicine, made for a lively conference. New...
Several Heart Institute staffers offered their expertise in invited talks touching on a broad range of topics. Scientist Erik Suuronen, PhD, uses tissue engineering techniques to develop methods for regenerating damaged heart muscle. In his presentation, called “The Matrix: Stem Cell Delivery...
Some of the biggest news to come out of AHA this year was the results from preliminary clinical trials of two new LDL cholesterol-lowering drugs that show a substantial decrease in LDL levels well below the reductions seen with statins or ezetimibe alone. The new drugs belong to a class called PCSK9...
The use of stem cells for regenerating damaged heart tissue offers great potential, but many technical questions remain. Understanding which cell types are most beneficial and how they should be employed is a central issue. Several clinical trials involving stem cells were presented at AHA. Two were...